Science
Our unique dual-targeted approach leverages an innovative proprietary platform to optimize the function of natural killer cells, thus maximizing cancer cell killing.
Partnering
We are interested in working with innovative industry partners and academic centers of excellence to progress the science and understanding of natural killer cells.
Latest News
- ONK Therapeutics Closes New Financing and Appoints Chris Nowers as CEO 19 October 2020
- ONK Therapeutics and biotech company Avectas has signed a collaborative deal for Avectas to licence a therapy from ONK Therapeutics that targets blood cell cancers such as non-Hodgkin’s lymphoma and certain forms of leukaemia. 16 May 2020
Careers
We are building a disciplined approach, an exciting team culture and a strong focus on operational excellence in all we do. As we are rapidly expand the company, we are looking for dedicated professionals to join our team and help drive progress in this evolving arena of medicine.
